First Trust Nasdaq Pharmaceuticals ETF (FTXH)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in First Trust Nasdaq Pharmaceuticals ETF, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

First Trust Nasdaq Pharmaceuticals ETF (FTXH) has returned 4.48% so far this year and 26.79% over the past 12 months.

Based on dividend-adjusted daily data since Sep 22, 2016, FTXH's average daily return is +0.03%, while the average monthly return is +0.65%. At this rate, your investment would double in approximately 8.9 years.

Historically, 57% of months were positive and 43% were negative. The best month was Apr 2020 with a return of +15.1%, while the worst month was Dec 2018 at -11.3%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.

On a daily basis, FTXH closed higher 47% of trading days. The best single day was Mar 24, 2020 with a return of +8.2%, while the worst single day was Mar 12, 2020 at -7.4%.

First Trust Nasdaq Pharmaceuticals ETF has an annualized alpha of 0.29%, beta of 0.62, and R² of 0.38 versus S&P 500 Index. Calculated based on daily prices since September 23, 2016.

• This ETF participated in 87.97% of S&P 500 Index downside but only 69.87% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.62 may look defensive, but with R² of 0.38 this ETF is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this ETF's risk.
• R² of 0.38 means the benchmark explains less than half of this ETF's behavior — treat beta with caution or consider switching to a more representative benchmark.

FTXH has an expense ratio of 0.60%, placing it in the medium range.

FTXH ranks 66 for risk / return — better than 66% of ETFs on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for First Trust Nasdaq Pharmaceuticals ETF (FTXH) and compare them to a chosen benchmark (S&P 500 Index).

First Trust Nasdaq Pharmaceuticals ETF provided a 1.23% dividend yield over the last twelve months, with an annual payout of $0.42 per share. The fund has been increasing its distributions for 6 consecutive years.

The table displays the monthly dividend distributions for First Trust Nasdaq Pharmaceuticals ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the First Trust Nasdaq Pharmaceuticals ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the First Trust Nasdaq Pharmaceuticals ETF was 32.11%, occurring on Mar 23, 2020. Recovery took 82 trading sessions.

The current First Trust Nasdaq Pharmaceuticals ETF drawdown is 3.36%.

The chart below shows the rolling one-month volatility.